At the beginning of this decade, when the fallout of the financial crash was still being felt and traditional venture firms were struggling to raise money, the investment arms of big pharma companies stepped in to fill a funding gap that was starving start-ups. Fast forward to the current period of plenty and, while corporate cash is no longer quite so crucial to the ecosystem, many of these units remain enthusiastic backers of early-stage science.